Cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D): Analysis by age group.
Zafar Malik
Honoraria - Astellas Pharma; AstraZeneca; GlaxoSmithKline; Janssen; Novartis; Pfizer; Sanofi
Giuseppe di Lorenzo
No relevant relationships to disclose
Sergio Bracarda
Consultant or Advisory Role - Bayer; Janssen
Honoraria - Janssen
Alexandros Ardavanis
Employment or Leadership Position - Department of Medical Oncology St. Savas Hospital
Honoraria - Novartis; Sanofi
Mert Basaran
No relevant relationships to disclose
Phillip Parente
Consultant or Advisory Role - Sanofi
Wito de Schultz
No relevant relationships to disclose
Fred Saad
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Inge van Oort
Honoraria - Sanofi
Winald R. Gerritsen
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Luis M. Antón Aparicio
Employment or Leadership Position - Complejo Hospitalario Universitario de A Coruna
Geoffrey Matus
No relevant relationships to disclose
Simon Hitier
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Axel Heidenreich
Consultant or Advisory Role - Amgen; Astellas Pharma; Janssen; Pfizer; Sanofi ; Takeda
Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi ; Takeda
Research Funding - Astellas Pharma; Sanofi
Amit Bahl
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi